Meeting
2020 Genitourinary Cancers Symposium
Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295.
Authors
Nabil Adra
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Nabil Adra , Ralph J. Hauke , Hristos Z. Kaimakliotis , Shuchi Gulati , Neda Hashemi , Roberto Pili
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03737123
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS587)
Abstract #
TPS587
Poster Bd #
N5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of FDA label change on immunotherapy for metastatic urothelial cancer (mUC) and subsequent changes in mortality.
First Author: Daniel Vader
Poster
2019 Genitourinary Cancers Symposium
A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).
First Author: Guru Sonpavde
Poster
2018 ASCO Annual Meeting
Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.
First Author: Alejo Rodriguez Vida
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar